American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
 - EconoTimes)
NEW YORK, Dec. 20, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into NovoCure Limited (NVCR) (“NovoCure”). If you are a NovoCure shareholder, you are encouraged to contact Scott+Scott at (800) 404-7770, email [email protected] or go to: http://www.scott-scott.com/cases/investigations/securities-fraud-litigation-3079-novocure-limited.html.
NovoCure develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (“TTFields”). NovoCure markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.
On July 28, 2016, NovoCure announced that its new Optune prescriptions fell to 657 in 2Q from 755 in 1Q. Asaf Danziger, Chief Executive Officer of Novocure stated that “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
On this news, NovoCure’s stock fell from a July 27, 2016 price of $11.44 to a July 28, 2016 price of $8.09, a one-day decline of over 29%.
If you are a NovoCure shareholder and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Michael Burnett at (800) 404-7770, or at [email protected].
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott have significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]
